ERBB2 and breast cancer: This study suggests that CLEC3A, PCDH10, and ST3GAL1 are associated with endocrine resistance and can reflect the prognosis of ER+HER2- BC patients receiving endocrine therapy, providing potential therapeutic targets and a valuable prognostic indicator for clinicians.